25 related articles for article (PubMed ID: 15143385)
1. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis.
Gong L; Wu D; Zou J; Chen J; Chen L; Chen Y; Ni C; Yuan H
Oncotarget; 2016 Apr; 7(14):18458-68. PubMed ID: 26918342
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients.
Li M; Xiao T; Zhang Y; Feng L; Lin D; Liu Y; Mao Y; Guo S; Han N; Di X; Zhang K; Cheng S; Gao Y
Lung Cancer; 2010 Sep; 69(3):341-7. PubMed ID: 20060194
[TBL] [Abstract][Full Text] [Related]
4. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
5. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
6. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients.
Kaya A; Gülbay BE; Gürkan OU; Celik G; Savaş H; Savaş I
Tuberk Toraks; 2003; 51(4):380-4. PubMed ID: 15143385
[TBL] [Abstract][Full Text] [Related]
8. Circulating apoptotic markers in the management of non-small cell lung cancer.
Holdenrieder S; Stieber P
Cancer Biomark; 2010; 6(3-4):197-210. PubMed ID: 20660965
[TBL] [Abstract][Full Text] [Related]
9. Circulating biomarkers for lung cancer.
Buccheri G
Ann Ital Chir; 1999; 70(6):831-8. PubMed ID: 10804657
[TBL] [Abstract][Full Text] [Related]
10. [Role of tumour markers in monitoring and follow-up of colorectal cancer patients].
Beczássy E; Ottó S; Vámosi Nagy I
Magy Onkol; 2004; 48(1):57-61. PubMed ID: 15105897
[TBL] [Abstract][Full Text] [Related]
11. The Role of Matrix Metalloproteinase-9 (MMP-9) as a Prognostic Factor in Epithelial and Lymphatic Neoplasia.
Pârvănescu V; Georgescu M; Georgescu I; Șurlin V; Pătraşcu Ș; Picleanu AM; Georgescu E
Chirurgia (Bucur); 2015; 110(6):506-10. PubMed ID: 26713823
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2817-9. PubMed ID: 10470248
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
